Loading
Thena Biotech packs chemotherapy inside cages made from a natural human protein, ferritin, which tumour cells take up readily, to deliver the drug to cancer cells with fewer side effects.
Thena Biotech S.r.l., headquartered in Latina, Italy, is an early-clinical-stage company developing biotherapeutics based on human ferritin (HFt) nanocages, which it describes as natural nanocarriers with intrinsic tumour-targeting properties. Its TARGETED technology delivers chemotherapy drugs inside ferritin nanocages, and its BOOSTER technology delivers bioactive peptides to tumours using engineered ferritin. THE-0504, given intravenously, is in a single-centre phase 1 dose-escalation trial in solid tumours, with small cell lung cancer and colorectal cancer among the listed conditions (NCT07646106). Its first registered cancer trial, NCT07646106, was posted on ClinicalTrials.gov in June 2026.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/